ArticleEMBO molecular medicine2023
LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma.
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
14.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 70 citations in OpenAlex.
- DMAMCL induces ferroptosis in neuroblastoma by targeting HMOX1 in MYCN-amplified subtypes whereas targeting STEAP3 in MYCN-nonamplified subtypes.Redox report : communications in free radical research · 2026Article
- LncRNA CCDC152 coordinates a tumor-associated selenoprotein P cycle that sustains selenium-dependent redox homeostasis in glioblastoma.Redox biology · 2026Article
- Targeted extracellular degradation of LRP8 promotes ferroptosis in cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Cuproptosis and ferroptosis: signal pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- A novel role for transcription factor NFE2 in redox regulation and chemotherapy resistance in acute myeloid leukemia.Leukemia · 2026Article
- Emerging tools to investigate the contribution of selenium to ferroptosis and beyond.Nature chemical biology · 2026Review
- Targeting oncogenic FLT3 uncovers a ferroptosis vulnerability through selenocysteine recoding in acute myeloid leukaemia.Nature cell biology · 2026Article
- Dual lipid modulation overcomes ferroptosis resistance in high-risk neuroblastoma.Cell death and differentiation · 2026Article
- A GPX1-OSBPL8 axis mediates noncanonical in vivo ferroptosis and cancer growth suppression.Cell · 2026Article
- Riboflavin metabolism shapes FSP1-driven ferroptosis resistance.Nature cell biology · 2026Article
- Genetics of selenoproteins and selenoprotein metabolism - An overview of current concepts and emerging aspects.Redox biology · 2026Review
- Dissecting Complex Interactions Between Ferroptosis and the Proteasome.bioRxiv : the preprint server for biology · 2026Article
- Ferroptosis in Glioblastoma and Neuroblastoma: Molecular Mechanisms and Novel Therapeutic Strategies.Current issues in molecular biology · 2026Review
- Exploring the Beneficial Effects of Se-Methylselenocysteine on GC-1/GC-2 Cells: From Cellular Uptake to Metabolic Pathway Regulation in Male Reproduction.Antioxidants (Basel, Switzerland) · 2026Article
- LRP8 Promotes colorectal cancer progression by suppressing ferroptosis through the SLC3A2/GPX4 signalling axis.European journal of medical research · 2026Article
- Research progress on the regulation of ferroptosis in NPC (Review).Oncology reports · 2026Review
- Regulation of apoptosis, ferroptosis, and pyroptosis mediated by acetylation.Cell death discovery · 2026Review
- Iron: Regulation, redox homeostasis, and ferroptosis in cancer.Ferroptosis and oxidative stress · 2026Article
- Fueling Death: The Metabolic Control of Ferroptosis.Advances in experimental medicine and biology · 2026Review
- Defining treatment-resistant brain cancer: Genetic screening to identify oncogene-driven immunomodulation and therapy resistance.Cancer gene therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 10 institutions in 4 countries.
Hamed Alborzinia *Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany.ORCID 0000-0001-6903-3001
Zhiyi Chen *Rudolf Virchow Zentrum (RVZ), Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany.ORCID 0009-0006-8826-647X
Umut Yildiz *Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany.ORCID 0000-0002-7175-362X
Florencio Porto FreitasRudolf Virchow Zentrum (RVZ), Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany.ORCID 0000-0002-0369-4488
Felix C E VogelDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-4067-2074
Julianna Patricia VargaHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany.
Jasmin BataniRudolf Virchow Zentrum (RVZ), Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany.
Christoph BartenhagenCenter for Molecular Medicine Cologne (CMMC) and Department of Experimental Pediatric Oncology, University Children's Hospital, Medical Faculty, University of Cologne, Cologne, Germany.
Werner SchmitzDepartment of Biochemistry and Molecular Biology, Theodor Boveri Institute, Biocenter, University of Würzburg, Würzburg, Germany.ORCID 0000-0003-0485-7303
Gabriele BüchelMildred Scheel Early Career Center, University Hospital Würzburg, Würzburg, Germany.
Bernhard MichalkeResearch Unit Analytical BioGeoChemistry, Helmholtz Center München (HMGU), Neuherberg, Germany.ORCID 0000-0001-6376-2588
Jashuo ZhengInstitute of Metabolism and Cell Death, Helmholtz Zentrum München (HMGU), Neuherberg, Germany.ORCID 0000-0002-5387-1358
Svenja MeierjohannDepartment of Pathology, University of Würzburg, Würzburg, Germany.
Enrico GirardiCeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Elisa EspinetAnatomy Unit, Department of Pathology and Experimental Therapy, School of Medicine, University of Barcelona (UB), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-0690-9878
Andrés F FlórezDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.
Ancely Ferreira Dos SantosRudolf Virchow Zentrum (RVZ), Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany.
Nesrine ArouaHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany.
Tasneem CheytanHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany.
Julie HaenlinHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany.
Lisa SchlickerDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-8350-2289
Thamara N Xavier da SilvaDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-5236-8470
Adriana PrzybyllaHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany.
Petra ZeisbergerHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany.
Giulio Superti-FurgaCeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Martin EilersDepartment of Biochemistry and Molecular Biology, Theodor Boveri Institute, Biocenter, University of Würzburg, Würzburg, Germany.ORCID 0000-0002-0376-6533
Marcus ConradInstitute of Metabolism and Cell Death, Helmholtz Zentrum München (HMGU), Neuherberg, Germany.ORCID 0000-0003-1140-5612
Marietta FabianoInstitut für Biochemie und Molekularbiologie, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.ORCID 0000-0002-4360-6809
Ulrich SchweizerInstitut für Biochemie und Molekularbiologie, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.ORCID 0000-0003-1380-4780
Matthias FischerCenter for Molecular Medicine Cologne (CMMC) and Department of Experimental Pediatric Oncology, University Children's Hospital, Medical Faculty, University of Cologne, Cologne, Germany.ORCID 0000-0003-1363-1242
Almut SchulzeDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Andreas TrumppHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany.ORCID 0000-0002-6212-3466
José Pedro Friedmann AngeliRudolf Virchow Zentrum (RVZ), Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany.ORCID 0000-0001-7706-1379
German Cancer Research Center · DEUniversity of Würzburg · DEHelmholtz Zentrum München · DEAustrian Academy of Sciences · ATUniversity of Bonn · DEUniversity of Cologne · DEEuropean Molecular Biology Organization · DEHarvard University · USInstitut d'Investigació Biomédica de Bellvitge · ESUniversitätsklinikum Würzburg · DE
Funding
European Research Council 695214European Research Council GA 884754Marie Curie MSCA-IF-2014-661491
Abstract
Ferroptosis has emerged as an attractive strategy in cancer therapy. Understanding the operational networks regulating ferroptosis may unravel vulnerabilities that could be harnessed for therapeutic benefit. Using CRISPR-activation screens in ferroptosis hypersensitive cells, we identify the selenoprotein P (SELENOP) receptor, LRP8, as a key determinant protecting MYCN-amplified neuroblastoma cells from ferroptosis. Genetic deletion of LRP8 leads to ferroptosis as a result of an insufficient supply of selenocysteine, which is required for the translation of the antiferroptotic selenoprotein GPX4. This dependency is caused by low expression of alternative selenium uptake pathways such as system Xc
Indexed as
FerroptosisNeuroblastomaAnimalsCell Line, TumorHumansLDL-Receptor Related ProteinsN-Myc Proto-Oncogene ProteinSelenocysteineLDL-Receptor Related Proteinslow density lipoprotein receptor-related protein 8MYCN protein, humanN-Myc Proto-Oncogene ProteinSelenocysteineferroptosisneuroblastomaselenocysteineselenoproteinsynthetic lethality
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.